Tuesday, 12 April 2016 10:31

Glaxo’s Potential Cure for “Bubble Boy Disease” One Step Closer

Written by 
Rate this item
(1 Vote)

Glaxo’s Potential Cure for “Bubble Boy Disease” One Step Closer

A potential cure for children born with a form of an extremely rare immune-system condition often referred to as “bubble-boy disease” has moved a step closer to approval after receiving the support of a European Union regulatory panel.


The treatment, which involves inserting a new gene into the patient’s stem cells, received a positive opinion from the European Medicines Agency’s advisory committee on Friday, paving the way for final approval in coming months.

It is aimed at children with a disease known as ADA-SCID, a rare condition in which a single genetic defect prevents sufferers from developing a robust immune system, leaving them very susceptible to infections. Without treatment, they rarely live for more than two years.

Currently, the best available option is a bone-marrow transplant, but success heavily depends on how well matched the donor is. For the one in four babies who have a well matched family member, a transplant can be an effective cure. But for the rest, success rates can be as low as 50%, according to Bobby Gaspar,professor of pediatrics and immunology at London’s Great Ormond Street Hospital.

The new therapy, called Strimvelis, was developed by a group of scientists and doctors based in Milan who have used it to treat 22 children over the past 14 years. All are still alive, most without needing any further treatment. In 2010, GlaxoSmithKline PLC struck a licensing deal for the rights to market the therapy.

If approved, it would be only the second gene therapy to be sold in Europe, after UniQure NV’s Glybera for a rare genetic condition in which the body can’t break down fat molecules. No gene therapies are approved for sale in the U.S.

The ADA-SCID gene therapy has moved at a cautious pace. Scientists tested an older form of gene therapy in children with the disease as early as 1990, but suffered a setback when, around 10 years later, several of those patients developed a leukemia-like condition.

“To be recognized as a licensed medicine shows gene therapy has come a long way forward,” Dr. Gaspar said.

One complication of administering Strimvelis: For now, it can be performed only in the Milan hospital where it was developed. The procedure involves removing some stem cells from the patient, applying the gene therapy outside the body and then reinjecting them, all of which must be done in quick succession to keep within the short “shelf life” of stem cells.

Parents will probably be willing to take their babies to Milan for treatment if it is considered the best option: Children from as far away as the U.S. and the Middle East came to Italy to take part in the clinical trial, according to Martin Andrews, head of the company’s rare-disease unit. Still, Glaxo aims to eventually make the therapy available in several “hubs,” and is working on methods to increase the shelf life of stem cells so that the procedure could be done remotely, by sending the child’s stem cells to a central facility for the gene therapy, he said. Glaxo also plans to seek approval from America’s Food and Drug Administration in 2017.

While Strimvelis is unlikely to move the needle for Glaxo in terms of revenue—around 14 babies are born with the condition every year in Europe—the company is betting that the technology can be used as the basis for several new treatments, Mr. Andrews said.

Rare diseases have drawn increasing interest from drugmakers in the past few years because the industry can command high prices for effective treatments in diseases with few other available therapies.

“If efficacy is demonstrated, payers are willing to reimburse [the companies],” said Mladen Tomich, head analyst for rare diseases at health-care consultancy Decision Resources Group. “While the price tag is high the overall expenditures are still limited due to the small patient population.”

Mr. Andrews didn’t disclose Glaxo’s pricing plans for the treatment but said it was considering flexible pricing models, including amortizing the payment over several years.



Read 226048 times Last modified on Tuesday, 12 April 2016 10:52

Latest from [email protected]


  • Comment Link breakfast caterer toronto Sunday, 26 February 2017 16:35 posted by breakfast caterer toronto

    Hey There. I found your blog using msn. This is a
    very well written article. I will make sure to bookmark it and come back to
    read more of your useful information. Thanks for the post.
    I will certainly comeback.

  • Comment Link Eileen Sunday, 26 February 2017 16:33 posted by Eileen

    Procure certo cabeceira dentre cetim ao invés com um pulvinar dentre
    algodão, entretanto levante petrechos pode invocar senhor derme obsceno. http://www.gd-hualida.com/comment/html/index.php?page=1&id=12868

  • Comment Link sky customer service Sunday, 26 February 2017 16:30 posted by sky customer service

    My partner and I stumbled over here by a different web page and thought I should check things out.
    I like what I see so now i am following you. Look forward to going over your web page again.

  • Comment Link Bernd Sunday, 26 February 2017 16:23 posted by Bernd

    Estou no 5 costume de terapia, querido cabeça está substancial a que ponto data primeiro e continuarei ate preencher os 6 meses. http://nitiankj.com/comment/html/index.php?page=1&id=40554

  • Comment Link breakfast caterer toronto Sunday, 26 February 2017 16:20 posted by breakfast caterer toronto

    Excellent pieces. Keep writing such kind of information on your site.

    Im really impressed by your blog.
    Hi there, You've done an excellent job. I will certainly digg it and for my part recommend to my friends.

    I'm confident they will be benefited from this web site.

  • Comment Link catering toronto Sunday, 26 February 2017 16:16 posted by catering toronto

    It's appropriate time to make some plans for the future and it is time to be happy.
    I've read this post and if I could I wish to suggest you some interesting things or advice.
    Perhaps you could write next articles referring to this article.
    I desire to read more things about it!

  • Comment Link beatcoin.info Sunday, 26 February 2017 16:12 posted by beatcoin.info

    Realidade com lanhar corrente consternação crina recusa interfere ante teu bulbo
    capilar, prudente por lhe subida. http://beatcoin.info/qtoa/index.php?qa=276&qa_1=segundo-simular-cabelo-concluir-contrair-disso-outros-salubre

  • Comment Link best dating advice Sunday, 26 February 2017 16:12 posted by best dating advice

    Do we say as it's a normal element to express, because for your
    important things about saying it only, because we have hardly anything else to express
    or perhaps it the circumstances are songs on the enjoying of this
    other individual. Instead of creating a high pressure situation which has
    a flamboyant or exuberant dinner, try and plan a pursuit to
    create both you and your date closer, and that you may know to your greater extent about each other.

    The second most important key totally free online chat is ensuring you might be noticed.

  • Comment Link Tangela Sunday, 26 February 2017 16:08 posted by Tangela

    SEO experts could install these tags within HTML codes as if they will certainly
    be indexed by spider programs made use of by
    search engines to note web pages.

  • Comment Link alquiforma.com Sunday, 26 February 2017 16:07 posted by alquiforma.com

    Este sitio es solo una pagina de información sobre los productos Bellavei y donde pueden comprarlos, Esta sitio no es la pagina
    oficial, Para ir a la pagina oficial DALE CLICK AQUI En este sitio los enlaces redirigen a
    la pagina ofifcial de productos bellavei. http://www.alquiforma.com/ActivityFeed/MyProfile/tabid/60/userId/6838/Default.aspx

Leave a comment

Make sure you enter the (*) required information where indicated. HTML code is not allowed.